ZVRA — ZEVRA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1434647 ·
Last close
$11.04
Market Cap
$655.60M
52W High
$15.03
52W Low
$8.01
ADV30
858,550
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 39,663,000 | 38,138,000 | 16,777,000 | 8,752,000 | 302,712,000 | 145,321,000 | 85,060,000 |
| Mar 2026 | 36,220,000 | 34,323,000 | 8,832,000 | 37,890,000 | 278,579,000 | 95,595,000 | 72,775,000 |
| Dec 2025 | 34,125,000 | 32,605,000 | 9,315,000 | 12,165,000 | 284,731,000 | 62,406,000 | 130,074,000 |
| Sep 2025 | 26,063,000 | 24,825,000 | 4,143,000 | -544,000 | 270,116,000 | 54,439,000 | 136,951,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$33,399,000
Investing CF
$106,720,000
Financing CF
$-42,143,000
CapEx
$-1,019,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$1.94
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-375,418,000
Inventory
$2,449,000
Receivables
$22,489,000
ST Investments
$76,249,000
EBIT TTM
$74,997,000
Pretax Income TTM
$69,287,000
Interest Exp TTM
$5,710,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$136,071,008
EBITDA
$40,553,000
Free Cash Flow
$48,381,124
Enterprise Value
$493,125,216
Total Cash
$221,570,000
Total Debt
$1,496,000
Shares Out
59,383,781
Trailing EPS
$0.93
Book Value
$3.67
ROE
34.8%
ROA
8.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 106,470,000 | -4,233,000 | 83,229,000 | 284,731,000 | 130,074,000 | 154,657,000 | -1,598,000 |
| Dec 2024 | 23,612,000 | -87,003,000 | -105,511,000 | 178,127,000 | 138,461,000 | 39,666,000 | -69,665,000 |
| Dec 2023 | 27,461,000 | -49,604,000 | -46,049,000 | 172,327,000 | 110,463,000 | 61,864,000 | -33,535,000 |
| Dec 2022 | 10,161,000 | -24,902,000 | -26,772,000 | 115,340,000 | 40,220,000 | 75,120,000 | -18,717,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$24,096,000
NetIncome TTM
$-36,324,000
OpCashFlow TTM
$0
Assets (Latest)
$284,731,000
Forward EPS
$1.08
Max Pain — expiry 2026-12-18
max pain strike: $8.00 · spot: $10.93 · call oi: 5,681 · put oi: 1,687
Expected Move to 2026-12-18:
±$2.33
(21.32%) —
implied range
$8.60 –
$13.26
· ATM straddle on $11.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | $660.06M | $20.22 | — |
| CLYM | Climb Bio, Inc. | $669.71M | $11.66 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $682.44M | $4.13 | — |
| ANNX | Annexon, Inc. | $690.07M | $3.64 | — |
| SLN | Silence Therapeutics plc | $694.88M | $11.18 | — |
News headlines (Yahoo Finance, 1h cache)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-21 20:30 · Yahoo
What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?
2026-08-07 05:12 · Yahoo
Zevra Therapeutics Q2 Earnings Call Highlights
2026-08-06 08:04 · Yahoo
Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ...
2026-08-06 05:08 · Yahoo
Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates
2026-08-06 00:35 · Yahoo
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
2026-08-05 20:05 · Yahoo
ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’
2026-07-24 18:43 · Yahoo
Zevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing Application
2026-07-24 14:38 · Yahoo
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
2026-07-22 11:30 · Yahoo
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
2026-06-23 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.